Analyses of immunity in pulmonary arterial hypertension (PAH) support the notion that maladaptation of the immune response exists. Altered immunity is an increasingly recognized feature of PAH. Indeed, a delicate balance between immunity and tolerance exists and any disturbance may result in chronic inflammation or autoimmunity. This is suggested by infiltration of various immune cells (e.g. macrophages, T and B lymphocytes) in remodeled pulmonary vessels. In addition, several types of autoantibodies directed against antinuclear antigens, endothelial cells (ECs) and fibroblasts have been found in idiopathic and systemic sclerosis-associated PAH. These autoantibodies may play an important role in EC apoptosis and in the expression of cell adhesion molecules. This review article provides an overview of immunity pathways highlighting their potential roles in pulmonary vascular remodeling in PAH and the possibility of future targeted therapy.
Introduction
Pulmonary arterial hypertension (PAH) is a group of the pulmonary hypertension (PH) classification and is defined by a mean pulmonary arterial pressure greater than 25 mmHg with a capillary wedge pressure ≤15 mmHg. PAH includes a heterogeneous group of clinical entities sharing similar pathological changes that have been subcategorized as familial PAH and idiopathic PAH. Pulmonary hypertension is associated with other diseases such as connective tissue diseases [CTD, e.g. systemic sclerosis (SSc), lupus erythematosus, and mixed CTD], portal hypertension and pulmonary hypertension related to HIV infection, drugs and toxins. PAH is characterized by severe pulmonary vascular remodeling and has long been associated with immune dysfunction. This pathological vascular remodeling is marked by excessive muscularization of the remaining pulmonary arteries and the formation of obstructive vascular lesions associated with the aberrant proliferation of endothelial cells (ECs), vascular smooth muscle cells (SMCs), and fibroblasts. The resulting elevation of pulmonary arterial pressure leads to right ventricular hypertrophy and death from right heart failure. Although PAH is primarily considered to be a vascular disease, there is a well-established link between PAH and immune dysfunction. However, little is known about the precise nature of altered immunity in PAH and how it might lead to vascular remodeling. Therefore, a better understanding of immunity pathways and their roles in the pathogenesis of PAH may help to develop targeted therapeutic approaches similar to those achieved from an improved understanding of endothelial dysfunction. This review will summarize recent progress in the research of immune cells ( Table 1 ) and autoantibodies (Table 2) in PAH and provide an overview of the immunity pathways involved in PAH.
Natural Killer Cells
Natural killer (NK) cells are best known for their ability to target and eliminate stressed, virally infected, or oncogene-transformed cells independent of specific antigen recognition. However, a growing body of literature supports a role for NK cells in a wide array of physiological processes, including the regulation of vascular remodeling and regeneration. A study of fourteen patients with PAH (9 IPAH, 5 CTD) showed that deficiencies in NK cells may be associated with an increased risk of death in PAH patients [1] , but further research is required in larger numbers of patients and to elucidate the mechanism of these findings. Ormiston et al. [2] found that the presence of NK cells is required to prevent monocrotaline-induced endothelial damage by infusion of human endothelial progenitor cells, supporting the idea of an integral role for NK cells in the endothelial progenitor cellmediated prevention of monocrotaline-induced PAH. Lately, they found that NK cells from patients with PAH also produced elevated quantities of matrix metallopeptidase 9, which is consistent with the capacity to influence vascular remodeling and a functional impairment of NK cells with regard to macrophage inflammatory protein 1β secretion and degranulation [3] . These results indicated that NK cells have beneficial effects on the pathogenesis of PAH.
Sasaki et al. [4] reported that apoptosis of pulmonary arterial ECs induced by anti-endothelial cell antibodies (AECA) in combination with activated NK cells may be the fist step of vascular damage associated with pulmonary hypertension in patients with mixed connective tissue disease (MCTD). However, examination of NK cells in lymphoid organs might also be important, because NK cells can kill immature dendritic cells, thus preventing the survival of lessimmunogenic immature dendritic cells, which would induce inappropriate, low-affinity T-cell priming [5] . Similarly, it has been shown that the transplantation of alloreactive NK cells can suppress T-cell-mediated graft-versus-host disease by eliminating host dendritic cells, resulting in a state of tolerance, or vice versa in the case of functionally impaired NK cells, resulting in the progression of chronic inflammatory diseases such as PAH. For the time being, further studies are necessary to characterize the exact pattern of NK cells in PAH-diseased lung.
CD8
+ Cytotoxic T Cells CD8 + T lymphocytes and NK cells originate from a common lymphoid progenitor cell, share parallel regulatory pathways, and primarily develop into 'professional killers' of cells corrupted with infection or tumors [6] . CD8 + lymphocyte depletion is a recognized adverse prognostic marker in cancer and chronic infections such as hepatitis C and human immunodeficiency virus [7] . CD8 + lymphocyte depletion is independently associated with death, decreasing 6-min walk distance and increasing NYHA classification [1] . Two other studies have reported alterations in the CD8 + compartment in PAH, but neither reported the clinical effect of lymphocyte deficiencies. Ulrich et al. [8] found that IPAH patients have decreased circulating cytotoxic CD8 + T lymphocytes. Austin et al. [9] found alterations in CD8 + subtypes but no significant difference in total CD8 + T lymphocytes between IPAH patients and controls. Edwards et al. [10] reported that two PAH patients sharing identical immune profiles (decreased NK cells and cytotoxic CD8 + T lymphocytes) died prematurely. Rajkumar et al. [11] reported that the CD8 + T cells formed a prominent component of vascular lesions. The perivascular CD8 + T-cell infiltration and accumulation in remodeled pulmonary vasculature may be associated with impaired EC apoptoticantiapoptotic signaling as observed in subjects with pulmonary hypertension. These results suggest that CD8 + T-lymphocyte depletion is present in some, but not all, PAH. Possibly, CD8 + T-cell depletion in PAH develops as the disease process deteriorates, which is analogous to the 'hierarchical CD8 + T-cell exhaustion' described in chronic viral models [7] . Phenotypic and functional analysis of CD8 + T cells from patients progressing through various stages of PAH may unravel the mechanistic role of cytotoxic CD8 + T cells in PAH pathogenesis. Further research is required in larger PAH [12] . Several studies using animal models have been done to explore the role of Th2 immune responses as instigators of PAH. For example, a Th2 response associated with sensitization to an antigen and subsequent challenge with that antigen can result in muscularization of smaller pulmonary arteries, and this response is associated with CD4 + cells and IL-13 [13] . The protein resistin-like alpha (Retnla; alias cysteine-rich secreted protein FIZZ1) can be induced by hypoxia, which is associated with vascular remodeling [14] . It is also induced in Th2 immune responses. Induction of an adaptive Th2 immune response in the lungs of mice suffices to cause pulmonary arterial muscularization, while depletion of the Th2 inflammatory cytokine IL-13 significantly attenuates such remodeling [15] . A key immune regulator candidate is vascular endothelial growth factor (VEGF), which can enhance Th2-mediated inflammation and has also been shown to play a critical role in the development of Th2-induced bronchial vascular remodeling [16, 17] . Graham et al. [18] [19] [20] have established a mouse model of schistosomiasis-induced PAH in which intraperitoneal sensitization with Schistosoma mansoni ova followed by intravenous augmentation with ova results in significant intrapulmonary Th2 inflammation coupled with pulmonary vascular remodeling and elevated right ventricular pressures. Chabon et al. [21] provided evidence that VEGF signaling is involved in the development of Th2 inflammation and vascular remodeling in the lungs of mice provoked by sensitization and intravenous exposure to Schistosoma ova, as evidenced by a decrease in Th2 inflammatory cytokines, perivascular inflammation, and pulmonary arterial medial thickening with concurrent pharmacological blockade of the VEGFRs, VEGFR1 and VEGFR2.
In some cases, the Th2-associated molecule resistin-like α (Retnla) appears to have a strong association with vascular remodeling and the resultant PAH, which may be related to its induction by hypoxia. Retnla itself is a potent stimulator of vascular remodeling [22, 23] . A mouse model of PAH with repeated inhalation of spores of the fungus Stachybotrys chartarum is also associated with the Th2 cytokines IL-4 and IL-5, but not with the Th1 cytokine IFN-γ [24] . Furthermore, Th2 cytokine IL-13 is implicated in schistosomiasis-induced PAH and several other forms of PAH [18, 25, 26] .
In contrast, Th1 immune responses, which are characterized by the secretion of cytokines such as IFN-γ and TNF-α and activation of phagocytic macrophages, appear to have little connection with the development of vascular remodeling and PAH. A few reports have demonstrated that elevated TNF-α is associated with clinical syndromes including PAH [27, 28] , but the association between PAH and the canonical Th1 cytokine IFN-γ still remains elusive. There is only one report showing that IFN-γ has a synergistic effect with other cytokines on in vitro pulmonary vascular cell remodeling [29] .
Indeed, the fact that IFN-γ has been used in clinical treatment of idiopathic pulmonary fibrosis [30] , although with little effectiveness, even though ≤40% of patients with idiopathic pulmonary fibrosis also exhibit PAH. However, Swain et al. [31, 32] found that the Th1 cytokine IFN-γ and CD4
+ T cells are absolutely required for the development of PAH in mouse model, and that perivascular fibrosis does not appear to be a cause of PAH. The initiating triggers of these immunologic disorders and the exact mechanisms by which altered immune responses contribute to the disease development or progression of PAH still remain unknown. In the immune system, CD4
+ regulatory T lymphocytes (Treg) represent a key cell type. They are potent immunomodulators of the adaptive immune system, proinflammatory cytokine responses, and activation of monocytes/macrophages [33, 34] . The association between autoimmune disorders and PAH has been recognized for many years [35] [36] [37] [38] [39] [40] [41] . The absence of Treg cells in athymic nude rats leads to activated macrophage recruitment in lungs and exaggerated pulmonary vascular remodeling after vascular injury with the vascular endothelial growth factor receptor inhibitor SU-5416 [42, 43] . It has been demonstrated that Treg cells are dysfunctional in patients with IPAH and that this adaptive immune dysregulation may be partly caused by the excessive pulmonary EC-derived leptin present in these patients [44] , suggesting that leptin could represent a missing link between pulmonary endothelial dysfunction and immunologic disorders in IPAH. In the absence of appropriate Treg activity, pulmonary vascular injury may lead to progressive elevation of pulmonary artery pressure and PAH [45] . PAH is associated with aberrant Treg cell number and activity, Treg cell deficiency is a major contributor to PAH progression [46] . Pulmonary inflammation is a well-established phenomenon in PAH, and inflammation associated with immunodeficiency after EC destruction is the primary predisposing factor for PAH [47] . Treg cells regulate immune responses after a variety of inflammatory injuries [46] . Deficient Treg cell activity can result in a blunted response to inflammatory endothelial injury, thereby resulting in PAH. Therefore, Treg cells might be able to prevent PAH by suppressing vascular inflammation and limiting the propagation of vascular injury [47] . Additionally, pulmonary arterial SMCs might undergo aberrant proliferation under pathological conditions, which contributes to pulmonary artery remodeling and the development of PAH [48] . Recently, increased Th17 and decreased Treg cell concentrations were found in patients with connective tissue disease- [8, 9] . Moreover, Treg cell abnormality might not contribute to disease pathogenesis in particular patients [52] . However, investigators in one study speculated that the unexpected increase of circulating Treg cell in patients with idiopathic PAH might be the consequence of underlying pulmonary vascular events [53] . Circulating Treg cell function, rather than number, might be affected in this disease setting, and Treg cells might become hyporesponsive in patients with PAH, compared with in healthy controls [44] . The interplay between Treg cells and the pulmonary vasculature is complex and remains poorly understood. Despite extensive studies in patients with PAH, few therapies have been proved to be effective in improving clinical outcomes. The role of the immune system in modulating the progression of PAH has received increasing attention. Correction of the aberrant immune response with Treg cell therapy might provide innate protection against PAH, and may be a new therapeutic approach. In contrast, Th17 cells, a subset of IL-17-producing effector T cells, have a highly proinflammatory nature and are widely implicated in inflammatory and autoimmune diseases [54] . Clinical data have shown the significance of IL-17 for pulmonary hypertension associated with chronic inflammation. In particular, studies of pulmonary hypertension associated with SSc showed the correlation of markers for Th17 and Th2 responses, including IL-17 and IL-13, with disease severity [55] [56] [57] . Th17 responses-eliciting IL-17 have been identified as pathogenic mechanisms in many autoimmune diseases and in silica particle exposure-induced lung inflammation in mice [58] . IL-17 is thought to be an independent and crossinhibitory inducer of inflammation and is associated with tissue destruction/remodeling [59, 60] . It has been shown that IL-17-and IL-13-coinduced inflammation is a new template for biomarkers and a therapeutic target for the management of immune responseinduced pulmonary hypertension [61] , suggesting a critical role of IL-17 for the development of the pulmonary hypertension phenotype in mice.
When the dynamic balance between effector T cells and Treg cells is altered, immune reactions are shifted toward the predominance of immune-soothing or excessive ones. The involvement of Th17 cells in the pathogenesis of PAH has been poorly examined. Hautefort et al. [62] reported that PAH monocyte-derived dendritic cells (MoDCs) induced a higher activation and proliferation of CD4 + T cells, which is associated with a reduced expression of IL-4 (T helper 2 response) and a higher expression of IL-17 (T helper 17 response). Purified PAH CD4 + T cells expressed a higher level of IL-17 after activation than those of control subjects. Lastly, there was significant hypomethylation of the IL-17 promoter in the PAH blood DNA as compared with the control blood. Hashimoto et al. [63] found that block of IL-6 by MR16-1 effectively prevented hypoxicpulmonary arterial hypertension (HPAH) in mice. IL-6 plays critical roles in the hypoxia-induced accumulation of Th17 cells and M2 macrophages in the lungs, as well as in the up-regulation of IL-17
and IL-21 which are produced mainly by Th17 cells. IL-21 is also produced by Th17 cells and drives Th17 differentiation in an autocrine manner. IL-6/IL-21-signaling axis plays a critical role in the pathogenesis of PAH, which suggests that this signaling axis may yield potential therapeutic targets for the treatment of patients with PAH. In conclusion, dysregulated immune response associated with IPAH or hypoxia-induced PAH may be related in part to the increase of Th17 immune polarization.
B Lymphocytes
B lymphocytes (B-cells) are fundamental to the humoral immune response, because of their potential to differentiate into antibodyproducing plasma B-cells. B-cells also play a crucial role in cell-mediated immune regulation through antigen presentation, production of various cytokines, differentiation of T-effector cells, and collaboration with antigen-presenting DCs [64] . Antibodies directed against pulmonary ECs and fibroblasts have been found in PAH, indicating a role of B-cells in PAH [65, 66] . In addition, activation of B-cells in peripheral blood B lymphocytes and perivascular infiltration of B lymphocytes have been observed in patients with IPAH [67] . Ulrich et al. [68] found that upregulated transcripts in B-cells of IPAH patients are involved in vessel biology, vasomotor regulation, angiogenesis, and cell proliferation.
Patients with IPAH express a distinct RNA expression profile in their peripheral blood B lymphocytes, which clearly suggests an activation of Bcells when compared with healthy controls. The up-regulated transcripts described here may help to direct future research on the pathogenesis of PAH.
Dendritic Cells
Dendritic cells (DCs) which are crucial for the activation of naive T cells play an important role in the immune system as professional antigen-presenting cells. DCs have the ability to differentiate into other cell phenotypes including ECs, which is probably of great importance in the pathogenesis of vascular disorders [69] . In experimental PH and clinical PAH, accumulation of immature dendritic cells in remodeled pulmonary arteries has been demonstrated, suggesting that they may contribute to PAH immunopathology [70] . Accumulation of these professional antigen-presenting cells may involve the presentation of antibodies to ECs, fibroblasts and nuclear antigens that are found in the serum of patients with IPAH and collagen vascular disease-associated PAH [71, 72] . Wang et al. [73] reported a decrease in the percentage of monocyte-derived DCs (MoDCs) in the peripheral blood of IPAH patients, suggesting a Th1 immune reaction in the pathogenesis of IPAH. T-lymphocyte differentiation is a highly organized process controlled by DCs. Several studies suggest that disturbed DC function plays a critical role in the establishment of chronic inflammation and in the induction of autoimmunity as seen in a number of autoimmune disease states [74] [75] [76] . Chaumais et al. [77] demonstrated that under similar differentiation and activation conditions, IPAH MoDCs exhibit a profile of membrane costimulatory molecules similar to that of control MoDCs. GC (dexamethasone) decreased the activation of MoDCs. However, PAH MoDCs retained a higher level of the T-cell-activating molecules CD86 and CD40 after GC pretreatment when compared with control MoDCs.
IPAH MoDCs could induce a higher activation/proliferation of CD4 + T cells with a reduced expression of IL-4 (Th2 response) and a higher expression of IL-17 (Th17 response), which may be related to the higher expression of p40 by PAH MoDCs. PAH is associated with inflammatory response by a reduced DC response to GC and an increased stimulation of T cells [78] . In conclusion, the dysregulated immune response associated with IPAH or hypoxia-PAH may be related in part to DC dysfunction.
Macrophages
Recruitment of macrophages has been reported in primary PAH as well as in other forms of PAH, including high-flow congenital heart disease, scleroderma, and PAH-associated acute respiratory distress syndrome [79, 80] . Similarly, increased number of macrophages has been described in murine and rat lungs in response to chronic hypoxia and monocrotaline (MCT)-induced PAH [81] [82] [83] . In addition, macrophages have been implicated in infectious etiologies such as HIV-associated experimental PAH [84] , and human herpes virus infection is associated with vascular remodeling, perivascular macrophages, and lung fibrosis [85] . Even in patients with IPAH [86] , recruitment of lung macrophages is evident and has been associated with the unfolded protein response. It has been reported that the absence of normal Treg activity in athymic rats leads to activated macrophage recruitment following vascular injury with the vascular endothelial growth factor receptor (VEGFR) inhibitor, SU5416, and this macrophage recruitment occurs in close association with the development of PAH [87] . A useful simplification of the athymic/ immune dysregulation model is that following vascular injury in animals with a healthy immune systems, normal Treg activity skews macrophage responses to promote injury resolution, but without this Treg activity (as observed in T-cell deficient athymic rats) pulmonary macrophages become activated and participate in injury evolution [88] . Activation of macrophages is also closely linked to epigenetic changes that stimulate and induce proliferation of vascular fibroblasts in patients and in experimental animal models of PAH [89] . These features involve Histone deacetylase1 mediated activation of a host of proinflammatory cytokines. Altered metabolism involving a switch to glycolysis, fatty acid oxidation, and production of reactive oxygen species underlies an abnormal interaction of fibroblasts with macrophages. Reversing the metabolic phenotype can also reverse the pathologic features of PAH in terms of macrophage recruitment and activation. Recent evidence showed that macrophage GM-CSF and LTB 4 signaling pathways are involved in PAH development, consistent with a paradigm of cooperative interaction between these two pathways in regulating gene expression in inflammatory macrophages [90] .
The role of the macrophage in processes such as limb or cardiac regeneration and pathogen defense indicates that it is important to understand the behavior of this cell in the context of the vascular milieu. CD68
+ macrophages are prominent in advanced obliterative plexiform lesions observed in experimental and clinical PAH [91] [92] [93] [94] [95] [96] , and macrophage depletion or inactivation prevents PAH in several model systems including experimentally induced hypoxia-PAH and portopulmonary hypertension [97, 98] . Macrophage accumulation and activation in interstitial lung may lead to the release of a variety of proinflammatory cytokines which are capable of causing vasoconstriction, increasing vascular permeability, and inducing proliferation [83] .
However, another population of macrophage (alveolar macrophage) also plays a significant role in the mechanism of HPAH. Experimental depletion of alveolar macrophage attenuated the chronic hypoxia-induced increase in mean pulmonary arterial pressure [99] , which could be a potential target for the treatment of pulmonary hypertension.
Eosinophils
Accumulating evidence suggests that pulmonary vascular eosinophils infiltration is an important stimulus for the pathological changes seen in various types of PAH [100] . It has been demonstrated that, when pulmonary eosinophilic (allergic) inflammation is induced in mice by sensitization and challenge with high-dose of ovalbumin, mice develop prominent pulmonary vascular remodeling [101] . It has been suggested that eosinophils can stimulate pulmonary vascular remodeling by releasing their granule contents and directly stimulating PASMC proliferation in the vasculature [102] . Medoff et al. [103] suggested that eosinophils may be directly mitogenic for PASMCs via degranulation. Low level of adiponectin (APN) may increase eosinophilic inflammation in obese individuals. An unexpected novel finding of an increase in pulmonary arterial muscularization and pulmonary hypertension with APN deficiency in eosinophilic inflammation suggested that coexistence of inflammatory lung disease and obesity may predispose individuals to pulmonary hypertension due, in part, to the reduced plasma APN level. In summary, eosinophils play a critical role in the pathogenesis of vascular remodeling in models of PAH induced by allergic inflammation.
Crosby et al. [104] found that pulmonary vascular eosinophilic inflammation in response to parasite eggs may contribute to schistosomiasis-associated pulmonary hypertension (Sch-PH). However, eosinophils have no direct impact on traditional measures of helminth disease in the well-characterized mouse model of Schistosoma mansoni infection [105] , which suggests that it is unclear whether eosinophils are required for the development of Sch-PH, and more studies are needed to confirm the role of eosinophils in Sch-PH.
Mast Cells
Mast cells are mainly localized in mucosa and connective tissues exposed to the outside environment, which are critical for the activation of innate and adaptive immunity. Lung vascular remodeling is an important pathophysiological process in pulmonary hypertension, and it is likely that mast cells participate in this remodeling process [106] . The role of mast cells in the rat model of monocrotaline-induced PAH and in idiopathic PAH has been intensively studied [107] [108] [109] . The findings from animal models suggest that targeting mast cells in several etiologies of pulmonary hypertension may be helpful via amelioration of vascular remodeling. Treatments targeting mast/stem cell growth factor receptor (KIT) signaling have been tried in some subtypes of pulmonary hypertension, showing some evidence of impact on vascular remodeling and functional capacity. Patients with idiopathic PAH have marked infiltration of KIT + cells in the vicinity of remodeled pulmonary arteries with a predominant perivascular distribution. Of these KIT + cells, more than 50% are mast cells [110] . Mast cells may contribute to the dysfunctional angiogenesis by secreting vascular endothelial growth factor in PAH [111] [112] [113] , and there is evidence for an increased plasma VEGF level in PAH [114] . The perivascular mast cells observed in IPAH express chymase [115] [116] [117] . The activities of chymase suggest that it may be a key player in vascular remodeling and the regulation of vasomotor tone, as it can lead to localized production of angiotensin II, the activation of endothelins, and matrix metalloproteases. However, the findings from animal models suggest that mast cell chymase may be an important target for pulmonary hypertension associated with fibrosis [118] . Total serum tryptase has been found to be higher in IPAH than that in controls [119] , suggesting greater number of mast cells and/or increased mast cell activation.
Increased chymase positive mast cells were also found in these forms of PAH [120, 121] . It is likely that mast cells are involved in the vascular remodeling seen in a number of respiratory disorders. Animal models of hypoxic PAH suggested that mast cells are activated by hypoxia and are an important contributor to pulmonary hypertension, and that targeting their activation, mediators, and/or recruitment may have therapeutic potential [122] .
Chronic hypoxia increases the production of proteolytic enzymes in mast cells which are more able to disrupt collagen and facilitate the growth of vascular smooth muscle cells [123] . Administration of a serine proteases inhibitor or mast cell degranulation blockers at the onset of exposure to chronic hypoxia attenuates the development of hypoxic-pulmonary hypertension in experimental animals. Mast cell degranulation, release, and activation of mediators participated in processes of tissue remodeling appear to be important factors in the initial phase of hypoxia. Mast cells and mast cell-derived mediators may be promising targets for the treatment of PAH [124] . In PAH of different etiologies, mast cells accumulate around pulmonary blood vessels and contribute to vascular remodeling and PAH. Further studies are needed to determine if mast cell blockade and/or more potent mast cell-targeted therapies early in the course of the disease can impact the angiopathic processes and improve patients' outcome.
As discussed above, substantial advances in basic and experimental research have illustrated the role of inflammation and the underlying cellular and molecular mechanisms that contribute to PAH. Infiltration of inflammatory cells, such as dendritic cells, macrophages, mast cells, T lymphocytes, and B lymphocytes, in the vascular lesions, and an elevation of tissue/serum concentrations of proinflammatory cytokines and chemokines play a significant role in PAH. The connection between inflammation and PAH is now generally accepted, but one question still remains, i.e. it is unclear whether inflammation is sufficient for the development of PAH. Some classes of drugs, such as prostacyclins, approved for the treatment of PAH, and inhibitors of hydroxymethylglutaryl coenzyme A (statins) recently used in clinical trials, were shown to have antiinflammatory and immunomodulatory functions, which showed unexpected anti-inflammatory effects of existing therapies for PAH [125, 126] . Understanding the inflammatory pathways will possibly help to improve the current treatments by directly targeting effectors of inflammation. However, many of the molecular and cellular mechanisms remain to be explored. New insights into inflammation in PH may identify novel therapeutic strategies for the treatment of this devastating disease.
Autoantibodies
Several autoantibodies have been reported in PAH, in particular IPAH and SSc-PAH. For example, Perosa et al. [127] demonstrated that some SSc clinical features are associated with subspecificities of anti-centromeric proteins (CENP)-A antibodies. Moreover, it shows that a simple, inexpensive phage-based assay can predict which SSc patients have high sPAP or low DLCO, and who are at greater risk of developing PAH. Guerreso et al. [128] reported a unique case of PAH associated with anti-SSA/Ro antibodies in the absence of clinical signs of SS, which highlights the potential for further evaluation of anti-SSA/Ro antibodies as a possible PAH marker. Anti-U1 ribonucleoprotein (RNP) positivity is associated with distinct clinical characteristics and survival in connective tissue diseases (CTD)-and SSc-associated PAH. While hemodynamic parameters were similar in anti-U1 RNP-positive and anti-U1 RNP-negative patients, Sobanski et al. [129] suggested that anti-U1 RNP positivity could be a factor which can protect against mortality in CTD-and SScassociated PAH. Guo et al. [130] identified endothelin receptor type A (ETRA) autoantibodies as a biomarker for mechanistic relevance in SLE. These autoantibodies may mediate PAH development in SLE. Anti-Ang receptor type-1 and anti-endothelin receptor type A antibodies are more frequent in SSc-PAH/connective tissue disease-PAH compared with other forms of pulmonary hypertension, and may serve as predictive and prognostic biomarkers in SSc-PAH. Both antibodies may contribute to SSc-PAH via increased vascular endothelial reactivity and induction of pulmonary vasculopathy [131] . Arends et al. [132] found that IgG AECA could play a pathogenic role by inducing inflammatory injury of vascular endothelium, which is considered to be a key player in the initiation and progression of PAH.
PAH-SSc patients have been found to have antifibrillarin antibodies [133] , and the poorly characterized anti-EC antibodies which are correlated with digital infarcts [134] . Nicolls et al. suggested that anti-EC antibodies can activate EC, induce the expression of adhesion molecules, and trigger apoptosis, thus contributing to the pathogenesis of PAH [135] . Other antibodies reported in PAH-SSc include antibodies against fibrin-bound tissue plasminogen activator in patients with limited cutaneous SSc [136] and in IPAH patients with HLA-DQ7 antigen [137] , and anti-topoisomerase II-alpha antibodies, particularly in association with HLA-B35 antigen [138] . Autoantibodies from patients with CTD (antifibrillarin antibodies and anti-dsDNA) can upregulate adhesion molecules (e.g. endothelial leukocyte adhesion molecule-1) and histocompatibility complex class II molecules on human pulmonary arterial EC in vitro [139] , suggesting that an inflammatory process can lead to proliferation and remodeling of the pulmonary vasculature. The antifibroblast antibodies detected in the serum of PAH-SSc and IPAH patients has significant pathogenic importance, since fibroblasts are indispensible components of the pulmonary vascular wall remodeling in PAH, and can be found in the remodeled neointimal layer in both SSc-PAH and IPAH. These antibodies can activate fibroblasts and in turn induce collagen synthesis, which potentially contributes directly to the remodeling process.
Antibodies from sera of patients with SSc induce a pro-adhesive and proinflammatory response in normal fibroblasts [140] . Patients with IPAH and PAH-SSc have IgG antifibroblast antibodies present in their sera which have distinct reactivity profiles under these two conditions [141] . A two-dimension immunoblotting experiment showed that fibroblasts antigens which are recognized by serum IgG from IPAH and SSc-PAH patients include proteins involved in the regulation of cytoskeletal function, cell contraction, cell and oxidative stress, cell energy metabolism, and other pathways that play key roles in cell biology and maintenance of homeostasis [142] . Although the specific membrane antigen targeted by these autoantibodies has not yet been determined, it is likely that the antibodies can react with membrane components, since they typically bind to unpermeabilized fibroblasts, thereby mediating the release of cytokines and growth factors, which in turn might contribute to the pathogenesis of vascular remodeling in PAH.
Patients with IPAH have circulating autoantibodies against vascular wall components. Pathogenic antibodies may be generated in the tertiary (ectopic) lymphoid tissues (tLTs). Perros et al. [143] demonstrated that the presence of germinal center centroblasts, follicular dendritic cells, activation-induced cytidine deaminase, and IL-21 + PD1 + follicular helper T cells in tLTs, together with CD138 + plasma cell accumulation around remodeled vessels in areas of immunoglobulin deposition. The main features of lymphoid neogenesis, specifically in the lungs of patients with IPAH, provide new evidence for the immunological mechanisms under this severe condition. In addition, bronchus-associated lymphoid tissue expands in pulmonary hypertension and is autoimmunologically active. Loss of self-tolerance contributes to pulmonary vascular remodeling and pulmonary hypertension [144] . Lymphoid tissue-directed therapies may be beneficial in treating pulmonary hypertension. A better understanding of how autoimmunity can trigger PAH would be invaluable for the development of models of PAH pathogenesis and could promote the design of novel therapeutics which specifically address immune dysregulation.
Conclusions and Perspectives
Immune cells and autoantibodies play an important role in the vascular remodeling characteristic of PAH and might be important targets for PAH therapy. While preclinical trials targeting specific inflammatory pathways have shown promising results in animal models, translating these findings to human PAH remains largely unexplored. Recognizing the complexity of specific immunity pathways in animal models and human PAH, some of which may be predominant in certain forms of PAH but not in others, is important. However, deciphering their exact mechanisms of action in the process of pulmonary vascular remodeling will provide a wide spectrum of potentially novel targets for PAH therapy.
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